SRZN

SRZN

Surrozen Inc

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

Surrozen Inc develops antibody-based therapeutics targeting the Wnt pathway for tissue repair, focusing on diseases affecting the eye, liver, lung, and central nervous system, including diabetic macular edema and age-related macular degeneration.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$157today

Score Overview

1 Year
Score
Net Growth-280.76%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-67.37%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-360.91%
Net Trend25%
Net Income Consistency
Rev Growthโ€”
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

Surrozen Inc fundamental performance

Across Surrozen Inc's full reported history, from 2021 to 2025, revenue grew from $ 0.00 to $ 3M and net income went from -$ 52M to -$ 242M. Revenue increased in 25% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 24.19โ€”
1 Year2025-08-12
$ 10.61127.99%
5 Years2021-08-12
$ 153.75-84.27%
All Time2021-01-11
$ 151.65-84.05%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 3M-$ 242M$ 89M
2024$ 10M-$ 63M$ 34M
2023$ 12M-$ 43M$ 36M
2022$ 12M-$ 27M$ 75M
IPO2021$ 0.00-$ 52M$ 101M

Explore beyond SRZN

You're looking at Surrozen Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies